REFERENCES
- Brown S B, Mellish K J. Verteporfin: a milestone in opthalmology and photodynamic therapy. Expert Opin Pharmacother. 2001; 2: 351–261, [PUBMED], [INFOTRIEVE], [CSA]
- Schmidt-Erfurth U, Miller J W, Sickenberg M, Laqua H, Barbazetto I, Gragoudas E S, Zografos L, Piguet B, Pournaras C J, Donati G, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study. Arch Ophthalmol. 1999; 117: 1177–1187, [PUBMED], [INFOTRIEVE], [CSA]
- Smith W, Assik J, Klein R, Mitchell P, Klaver C CW, Klein B E, Hoffman A, Jensen S, Wang J J, deJong P TVM. Risk factors for age-related macular degeneration. Pooled findings from three continents. Ophthalmol. 2001; 108: 697–704, [CSA]
- Miller J W, Schmidt-Erfurth U, Sickenberg M, Pournaras C J, Laqua H, Barbazetto I, Zografos L, Piguet B, Donati G, Lane A M, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol. 1999; 117: 1161–1173, [PUBMED], [INFOTRIEVE], [CSA]
- Schmidt-Erfurth U, Michels S, Barbazetto I, Laqua H. Photodynamic Effects on Choroidal Neovascularization and Physiological Choroid. Invest Ophthalmol Vis Sci. 2002; 43: 830–841, [PUBMED], [INFOTRIEVE], [CSA]
- Ochsner M. Photophysical and photobiological processes in the photodynamic therapy of tumours. J Photochem Photobiol. B. 1997; 39: 1–18, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Lavie G, Mazur Y, Lavie D, Meruelo D. The chemical and biological properties of hypericin—a compound with a broad spectrum of biological activities. Medicinal Res Rev. 1994; 15: 111–119, [CSA]
- Blank M, Mandel M, Hazan S, Keisari Y, Lavie G. Anti-cancer activities of hypericin in the dark. Photochem Photobiol. 2001; 74: 120–125, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Lavie G, Meruelo D, Aroyo K, Mandel M. Inhibition of the CD8 T cell-mediated cytotoxicity reaction by hypericin. Potential for treatment of T-cell mediated diseases. Int Immunol. 2000; 12: 479–486, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Lavie G, Kaplinsky C, Toren A, Aizman I, Meruelo D, Mazur Y, Mandel M. A photodynamic pathway to apoptosis and necrosis induced by dimethyl tetrahydroxy helianthrone and hypericin in leukemic cells. Possible relevance to photodynamic therapy. Br J Cancer 1999; 79: 423–432, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Mossman T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunogen. 1983; 21: 235
- Keisari Y. A colorimetric microtiter assay for the quantitation of cytokine activity on adherent cells in tissue culture. J Immunol Methods. 1992; 146: 155–161, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann G O. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci. 2003; 44: 4473–4480, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Blank M, Mandel M, Keisari Y, Meruelo D, Lavie G. Enhanced ubiquitinylation of heat shock protein 90 as a potential mechanism for mitotic cell death in cancer cells induced with hypericin. Cancer Res. 2003; 63: 8241–8247, [PUBMED], [INFOTRIEVE]